Biocryst Pharmaceuticals (BCRX) Liabilities and Shareholders Equity (2010 - 2026)

Biocryst Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $465.1 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 3.12% year-over-year to $465.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (down 2.65% YoY) and the FY2025 annual result came in at $514.2 million, up 4.84% from the prior year.
• Liabilities and Shareholders Equity was $465.1 million for Q1 2026 at Biocryst Pharmaceuticals, down from $514.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $558.6 million in Q3 2022 and bottomed at $446.4 million in Q3 2025.
• A 5-year average of $500.7 million and a median of $509.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 110.19% — and 2024, when it dropped 10.84%.
• Biocryst Pharmaceuticals' Liabilities and Shareholders Equity stood at $550.0 million in 2022, then dropped by 6.01% to $517.0 million in 2023, then decreased by 5.13% to $490.4 million in 2024, then advanced by 4.84% to $514.2 million in 2025, then fell by 9.55% to $465.1 million in 2026.
• Business Quant data shows BCRX's Liabilities and Shareholders Equity at $465.1 million in Q1 2026, $514.2 million in Q4 2025, and $446.4 million in Q3 2025.